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Abstract
Although many advances in the understanding and treatment of schizophrenia have been made many
challenges still remain. Most notably is the lack of understanding pertaining to the negative symptoms
dimension of schizophrenia and the treatment of such symptomology? Primary negative symptoms
affect 20-40% of individuals with schizophrenia and are associated with the greatest impacts upon
functional impairment and quality of life. A qualitative review of the prevailing challenges related to the
nature, assessment and treatment of negative symptoms was conducted. The current literature in each of
the aforementioned areas pertaining to primary negative symptoms was reviewed with a focus upon the
key challenges and directions for future research. The results of the qualitative review indicate that the
construct of negative symptoms requires further delineation and recent work in the area of the
assessment of negative symptoms necessitates further development. In regards to the treatment of
negative symptoms no definitive directions are espoused due to the extent of the dearth of knowledge in
the area as highlighted in the discussion. The area of negative symptoms research requires multidisciplinary collaborative research to address the major challenges to the understanding, assessment and
treatment of negative symptoms in schizophrenia to improve the quality of life and functional outcomes
of those with primary negative symptoms.
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Abstract :
Although many advances in the understanding and treatment of schizophrenia have been made many challenges still remain. Most
notably is the lack of understanding pertaining to the negative symptoms dimension of schizophrenia and the treatment of such
symptomology? Primary negative symptoms affect 20-40% of individuals with schizophrenia and are associated with the greatest
impacts upon functional impairment and quality of life. A qualitative review of the prevailing challenges related to the nature,
assessment and treatment of negative symptoms was conducted. The current literature in each of the aforementioned areas pertaining
to primary negative symptoms was reviewed with a focus upon the key challenges and directions for future research. The results of the
qualitative review indicate that the construct of negative symptoms requires further delineation and recent work in the area of the
assessment of negative symptoms necessitates further development. In regards to the treatment of negative symptoms no definitive
directions are espoused due to the extent of the dearth of knowledge in the area as highlighted in the discussion. The area of negative
symptoms research requires multi-disciplinary collaborative research to address the major challenges to the understanding,
assessment and treatment of negative symptoms in schizophrenia to improve the quality of life and functional outcomes of those with
primary negative symptoms.
Keywords : Schizophrenia, Negative Symptoms, Assessment & Treatment

Introduction :

knowledge pertaining to negative symptoms in

Over the past decade or so several scientific advances have

schizophrenia spectrum disorders. Negative symptoms in

been made in the fields of genetics, biology and

schizophrenia are defined as a deficit or diminution of

pharmacology in relation to the epidemiology, diagnosis

normal functioning (Blanchard &Cohen, 2006; Stahl &

and treatment of schizophrenia and related disorders.

Buckley, 2007); historically negative symptomology were

Some examples include the exploration of biomarkers and

conceptualised as the core of the disorder (Bleuler, 1978;

candidate genes in the susceptibility and development of

Kraepelin, 2009). However since early conceptualisations

schizophrenia (DeRosse et al., 2008; Javitt, Spencer, Thaker,

negative symptoms have long been the neglected

Winterer, & Hajos, 2008; Pogue-Geile & Yokley, 2010), the

symptom dimension in the field (Kaiser, Heekeran & Simon,

identification of structural and functional brain

2011; Rector, Beck & Stolar, 2005; Turkington & Morrison,

abnormalities (Karlsgodt, Sun, & Cannon, 2010), and the

2012) despite the significant functional impairments that

trial of promising new medications in animal models and

are associated with such symptomology.

humans (Patil et al., 2007).
Access this article online
Quick Response Code

None the less, major
challenges remain.
Arguably the most

Schizophrenia in itself is a chronic and debilitating illness
that results in high levels of disability and functional
impairment (Makinen, Miettunen, Isohanni & Koponen,
2008); with approximately 20-40% of individuals

significant and pervasive

diagnosed with schizophrenia experiencing persistent and

challenge to the field

enduring negative symptoms (Makinen, Miettunen,

relates to the dearth of

Isohanni & Koponen, 2008). It is these individuals with
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enduring negative symptoms that are known to have

Schizophrenia itself is a complex and heterogeneous

significantly poorer functional outcomes, higher levels of

disorder; with positive symptomology, negative

long-term morbidity and greater familial burden than

symptomology, affective symptomology, disorganization

those with prominent positive symptoms (Bowie,

and cognitive deficits all interacting to add to the overall

Reichenberg, Patterson, Heaton, & Harvey, 2006; Kaiser,

complexity associated with the challenges pertaining to

Heekeran & Simon, 2011; Kirkpatrick, Fenton, Carpenter &

negative symptoms specifically. The complexity of this

Marder, 2006; Milev, Ho, Arndt, & Andreasen, 2005;

association is illustrated in Figure 1 below; in this figure it is

Rabinowitz et al., 2012). Further negative symptoms are

apparent that all five dimensions overlap with each other

often more stable and enduring over time than positive

as well as intersect altogether.

symptoms (Velligan et al., 2006). Thus negative symptoms,
such as the inability to experience pleasure, social
withdrawal, poverty of speech and decreased motivation
are often considered a major unmet need in health services
and medical research (Alphs, 2006).

Thus the complexity of schizophrenia as highlighted in the
diagram above is associated with several prevailing
challenges; these challenges are summarised in Box 1
below. The first challenge pertains to the nature of the
psychopathology associated with schizophrenia being truly

The National Institute of Mental Health (NIMH) released a

dimensional in nature; however the nomenclature

consensus statement on negative symptoms several years

attempts to categorise and award pseudo boundaries to

ago highlighting areas pertaining to negative

the symptomology. Similarly the second challenge relates

symptomology that require further research, clarification

to the issues associated with quantifying a phenomenon

and consensus (Kirkpatrick et al., 2006). Seven years on

that is in fact qualitative in nature; that is all individuals'

from the release of the consensus statement more work is

ex p e r i e n c e s c h i zo p h re n i a d i ffe re nt l y m a k i n g

required in the area of negative symptomology in order to

quantification of the dimensions problematic.

capitalise and advance upon the agreement and
developments spawned by the NIMH consensus statement
on negative symptoms (Kirkpatrick et al., 2006).

The third challenge pertains to the lack of a specific
treatment goal or target for treatment in the treatment of
schizophrenia. That is psychiatric diagnoses are symptom

Therefore this paper seeks to highlight key challenges that

based as such treatment is symptom based; hence the true

remain in negative symptom research and identify

underlying dimension is not being targeted in treatment.

imperatives for future research. The paper will firstly briefly

The last challenge noted above is the false assumption that

highlight the heterogeneous nature of schizophrenia in

schizophrenia results from a single aetiology rather than as

general and the associated challenges. Before highlighting

a result of multiple aetiologies. Or distinctive aetiologies

the challenges specific to negative symptomology as they

associated with each of the dimensions outlined above.

pertain to the nature of negative symptoms as well as their

These challenges; reflective of the nature of schizophrenia

assessment and treatment. Each section will conclude with

and our understanding of the disorder further complicate

recommendations for future research. With such research

the assessment and treatment of schizophrenia generally

having the potential to facilitate more effective

as well as impacting upon the negative symptom

assessment, treatment and management of negative

dimension specifically.

symptoms in schizophrenia and thus the ability to
significantly improve the quality of life of the 20-40% of

Box 1. The Prevailing Challenges in Schizophrenia
The Challenges
Dimensional versus Categorical Nature of Schizophrenia
Quantifying a Phenomenon that is Truly Qualitative in Nature
Lack of Specific Treatment Goal in Schizophrenia
The Pseudo-Assumption of a Single Aetiology of Schizophrenia

individuals with schizophrenia that experience persistent
and enduring negative symptoms.
Brief Overview of the Heterogeneous Nature of
Schizophrenia Generally
Keywords : Schizophrenia, Negative Symptoms, Assessment
& Treatment - Shae-Leigh C Vella
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Figure 1. The Heterogeneous Nature of Schizophrenia

Figure 2. The Inter-Relatedness of the Key Challenges
in Negative Symptom Research

Negative Symptoms: The Key Challenges

avolition as negative symptoms with anhedonia noted as

The following section summarises the current state of

an associated feature of schizophrenia. In contrast Arango

knowledge pertaining to negative symptoms; highlighting

and Carpenter (2011) ascertain that asociality and apathy

the key challenges and gaps in the area. Broadly there are

along with anhedonia are commonly also acknowledged to

three key challenges: firstly; what is the nature of negative

be negative symptoms in addition to affective flattening

symptoms, secondly; challenges pertaining to the

(blunted affect), alogia and avolition. Kirkpatrick and

assessment of negative symptoms and thirdly; challenges

colleagues (2006) in the NIMH consensus statement on

relating to the treatment of negative symptoms. Similarly

negative symptoms agreed that asociality, blunted affect,

to the nature of schizophrenia in general, these challenges

alogia, anhedonia and avolition currently constitute the

pertaining specifically to negative symptoms are not

negative symptom dimension. These symptoms

independent with each of the aforementioned challenges

acknowledged by the NIMH consensus statement on

being inter-related and as such hindering progress in each

negative symptoms are defined in Table 1 below.

of the respective areas. The inter-relatedness of these
challenges is illustrated in Figure 2 below. Further it is the

Table 1. Definitions of Negative Symptoms
Negative Symptom Definition*
Blunted Affect
Reduced emotional expression and
expressiveness.
Alogia
Poverty of speech or poverty of content of
speech.
Avolition
Lack of volitional action.
Asociality
Lack of interest in social contact and
experiences.
Anhedonia
Inability to experience pleasure.
*Definitions of symptoms' in the table above are derived from
Arango and Carpenter (2011).

author's viewpoint that the abovementioned order
accorded to the key challenges in negative symptoms
research highlights the hierarchical nature in which these
would most effectively be addressed with research in each
area informing research within the subsequent domains.
What is the Nature of Negative Symptoms?
A lack of consensus and consistency in the negative
symptomology construct has continued to hinder research
efforts in the area. Fundamentally there remains

In addition to the symptoms that comprise the negative

uncertainties in the symptoms' that comprise the negative

symptom dimension of schizophrenia there are also

symptom dimension (American Psychiatric Association,

questions pertaining to the factor structure of the

2000; Kirkpatrick, 2006; Arango & Carpenter, 2011).

construct (Blanchard & Cohen, 2006; Kirkpatrick & Fisher,
2006). For example is the construct of negative symptoms

With the DSM-IV-TR (American Psychiatric Association,

in schizophrenia uni-dimensional or multi-dimensional in

2000) listing affective flattening (blunted affect), alogia and

nature (Blanchard & Cohen, 2006; Kirkpatrick & Fisher,

Keywords : Schizophrenia, Negative Symptoms, Assessment
& Treatment - Shae-Leigh C Vella
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2006).

If the construct is multi-dimensional what is the

factor structure that underlies the construct (Blanchard &
Cohen, 2006; Kirkpatrick & Fisher, 2006).

Cohen, 2006).
Similarly others have questioned the definition of negative
symptoms (Messinger et al., 2011). With Messinger and

Recently Messinger and colleagues (2011) in a theoretical

colleagues (2011) highlighting that defining negative

review suggested that the symptoms of avolition and

symptoms as a diminution or deficit of normal functioning

affective deficits constitute the negative symptom domain.

as problematic due to the current understanding of

Similarly Horan and colleagues' (2011) found a two factor

cognitive processes in schizophrenia. However it should be

solution for a recently developed measure of negative

noted that this is the definition commonly utilised and

symptoms; the Clinical Assessment Interview for Negative

endorsed by the NIMH consensus statement on negative

Symptoms (CAINS). Specifically the factor structure could

symptoms (Kirkpatrick et al., 2006) and as such the

be broadly distinguished between experiential and

definition adopted in this article. However, future

expressive items (Horan et al., 2011). Furthermore in light

questioning and reframing of the definition based upon

of the aforementioned issues further clarification of the

strong empirical support may be needed.

nosology of negative symptomology is also needed
(Linscott & van Os, 2006; Parnas, 2011). As such
clarification is paramount to not only diagnosis, but also; to
research in general and more importantly the meaningful
interpretation and translation of results of empirical
studies into clinical practice (Erhart, Marder & Carpenter,
2006).

Thus it is clearly apparent that there remains a general lack
of consensus pertaining to the nature of negative
symptoms in schizophrenia. Table 2 below highlights some
of the key challenges in the area and the actions that are
required as well as the potential implications of such
research. Future research should seek to delineate and
validate an empirically founded definition of negative

In addition to the aforementioned issues and lack of

symptoms as well as clarifying the nosology of negative

consensus pertaining to negative symptomology some

symptoms. Further the symptoms that comprise the

researchers have even conjectured that the disease entity

negative symptom domain and the factor structure of the

( s c h i zo p h re n i a ) m a r ke d by p r i m a r y n e gat i ve

negative symptom domain also require clarification,

symptomology is not simply a distinct dimension rather it

delineation and consensus. Specifically, Erhart, Marder

indicates the presence of a separate disease; not

and Carpenter (2006) recommend the delineation of

schizophrenia (Carpenter, 2006; Carpenter, 2007; Kaiser,

whether negative symptoms are homogenous or

Heekeren & Simon, 2011). As factor analytic research

heterogeneous as well as categorical or dimensional. Such

commonly supports the notion of schizophrenia spectrum

work will greatly benefit the advancement of research

disorders being multi-dimensional in nature however

endeavours aimed at developing and improving the

inconsistencies to the factor structure of schizophrenia in

assessment and treatment of negative symptomology in

general remain (Lindenmayer, Grochowski & Hyman, 1995;

schizophrenia.

Toomey et al., 1997; Peralta & Cuesta, 2001; Blanchard &
Table 2. The Nature of Negative Symptoms: Challenges, Actions Required & Implications
Challenge
Consistency in the definition of the
domains of negative symptoms

Research / Action Required
Adoption of the NIMH Consensus
Statement of Negative Symptom
domains (Kirkpatrick et al., 2006)
Nomenclature for diagnosis that
encompasses these domains

Keywords : Schizophrenia, Negative Symptoms, Assessment
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Challenge
Identifying the true boundary
conditions of the negative
symptom construct

Consensus on the definition of
negative symptoms

Research / Action Required
Research to ascertain whether the five
domains specified by Kirkpatrick
et al. (2006) are the true boundaries
of the negative symptom construct.
Theorising as to the structure of the
negative symptom construct.
Research to clarify whether the current
definition of negative symptoms is flawed
due to our emerging understanding of
cognitive problems in schizophrenia
(Messinger et al., 2011).

Implications
An understanding of the true boundary
conditions and structure of the construct
has the potential to advance assessment
and treatment.

Clarification and delineation of the
relationship between negative symptoms
and cognition in schizophrenia has the
potential to lead to treatment interventions
for both issues. As well as the potential to
inform early intervention strategies.

The Assessment of Negative Symptoms

to the conceptualisation of the nature of negative

The very nature of negative symptoms makes assessment

symptoms (as discussed in the section above) with the

difficult for researchers and clinicians alike. Negative

nature of negative symptoms being reflective of how they

symptoms are insidious and represent an absence or

are assessed. Factor analysis of two of the most commonly

reduction of usual behaviours often making them difficult

utilised instruments for the assessment of negative

for clinicians to recognise and diagnose (Buckley & Stahl,

symptoms as suggested by Erhart, Marder and Carpenter

2007). Moreover negative symptoms can also impede the

(2006); the Scale for the Assessment of Negative

individual's ability to communicate their inner experiences

Symptoms (SANS: Andreasen 1982; Andreasen, 1983) and

and psychopathology (Fanous et al., 2012). Likewise there

the Schedule for Deficit Syndrome (SDS: Kirkpatrick et al.,

are also problems associated with detecting improvements

1989) indicate that they both assess more than a single

in negative symptomology over time (Stahl & Buckley,

factor. Suggesting that negative symptoms are multi-

2007).
Negative symptoms are not uni-factorial in origin (Toomey
et al., 1997), nor are they commonly considered to
represent a homogenous entity (Blanchard & Cohen,

dimensional in nature; well at least how they are
conceptualised and measured by the two aforementioned
instruments (Erhart, Marder & Carpenter, 2006).
Further the shortcomings of another commonly utilised

2006). Thus the distinction between primary negative

instrument for the assessment of negative symptoms the

symptoms; those that intrinsically reflect the core

Positive and Negative Syndrome Scale (PANSS: Kay, Fiszbein

symptoms of the disorder itself, and secondary negative

& Opler, 1987) have also been emphasized (Blanchard et

symptoms; those that result from other factors such as the

al., 2010). A summary of some of the criticisms of the

effects of antipsychotic treatment, positive symptoms,

PANSS are displayed in Box 2 below. For example the PANSS

extrapyramidal symptoms, depression or environmental

is exclusively reliant upon behaviour observed during the

under-stimulation remains elusive (Flaum & Andreasen,

process of the interview as well as the carer's perspective;

1995; Messinger et al., 2011). Further few have used

thus the ratings are devoid of the individual with

diagnostic and assessment scales to attempt to distinguish

schizophrenia perspective (Blanchard et al., 2010).

between primary and secondary negative symptoms. Thus,

Particularly troublesome is the lack of perspective that can

it is often unclear in antipsychotic outcome studies the

be provided by the client in response to experiential

origin of the negative symptoms that are responding (or

deficits (Blanchard et al., 2010; Forbes et al., 2010). Overall

not responding) to treatment (Murphy, Chung, Park, &

Blanchard and colleague's (2010) article highlighted the

McGorry, 2006).

limitations of the previously mentioned measures of

The assessment of negative symptoms is intimately linked
Keywords : Schizophrenia, Negative Symptoms, Assessment
& Treatment - Shae-Leigh C Vella
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instruments are out-dated and do not reflect the

2010; Horan et al., 2011). However Forbes and colleagues

contemporary understanding and current empirical

(2010) note that the latent structure of negative symptoms

findings pertaining to negative symptoms (Blanchard et al.,

remains undetermined. The development of the CAINS

2010).

also sought to overcome the reliance on behavioural and

Box 2. Criticism of the PANSS
Criticisms of the PANSS
The clinical implications of the PANSS scores are unclear
(Leucht et al., 2005).
The clinical meaning of the response cut-off scores employed
in clinical trials is also unclear due to the aforementioned issue
(Lancon et al., 1998; Leucht et al., 2005).
Key conceptual limitations. For example individual items
reflect several conceptually distinct domains (Blanchard et al.,
2010).
Behavioural measurement of experiential deficits (Blanchard
et al., 2010).
Uncertain factor structure (Lancon et al., 1998).

performance deficits that existed in the current scales thus
neglecting experiential deficits that can be considered the
core of the negative symptom construct (Forbes et al.,
2010). Thus the CAINS incorporates measures of
experiential deficits (Forbes et al., 2010; Horan et al.,
2011). Further the CAINS is in line with current empirical
research on motivation and hedonic experience in
schizophrenia; as it includes measures of both anticipatory
and consummatory pleasure (Strauss et al., 2011; Forbes et
al., 2010; Horan et al., 2011). Recently Barch (2013)
suggested that use of instruments such as the CAINS assists

The shortcomings of existing instruments summarised

with integrating our current understanding of affective

above is in accordance with the National Institute of

neuroscience into the assessment of schizophrenia.

Mental Health (NIMH) consensus statement on negative

The initial results from the early development and

symptoms suggestion for the development of a new

validation study of the CAINS showed overall support for

measure of negative symptomology in schizophrenia

the feasibility and validity of the instrument (Forbes et al.,

(Kirkpatrick et al., 2006; Blanchard et al., 2010). As the

2010). However there were issues pertaining to the

current instruments were impeding advancements in the

measurement of the intensity of hedonic experience in a

treatment of negative symptoms (Forbes et al., 2010).

population with vocabulary impediments and limited

As such a panel of experts convened and collaborated to

speech output (Forbes et al., 2010). Furthermore there

develop a new measure of negative symptoms to

were also issues evident in the measurement of asociality

overcome the shortcomings of the existing measures

specifically concerning how best to integrate the

(Forbes et al., 2010; Horan et al., 2011). It quickly became

information about different social relationships (family,

apparent that two instruments were required to remedy

romantic and friendships) to improve the consistency of

the current void that existed in the measurement of

the scale (Forbes et al., 2010).

negative symptoms specifically a longer more detailed

A factor analysis of preliminary CAINS data; has indicated a

instrument as well as a brief concise instrument suitable for

two factor structure to the negative symptom dimension

clinical trials (Kirkpatrick et al., 2011). Thus the CAINS

(Horan et al., 2011), namely; an experiential factor and an

(Forbes et al., 2010; Horan et al., 2011) and the Brief

expressive factor. With the experiential factor, being

Negative Symptom Scale (BNSS: Kirkpatrick et al., 2011;

composed of the symptoms of; avolition, anhedonia and

Strauss et al., 2012) were developed to meet both of the

asociality and the expressive factor comprised of; blunted

aforementioned challenges respectively.

affect (affective flattening) and alogia (Horan et al., 2011).

The CAINS was developed to measure the five domains of

Horan and colleagues (2011) concluded that the CAINS is

negative symptoms espoused by the NIMH consensus

displaying promising potential as a measure for the

statement on negative symptoms specifically; anhedonia,

assessment of negative symptoms.

asociality, avolition, alogia and blunted affect (Forbes et al.,

Although the CAINS is displaying promise not all individuals

Keywords : Schizophrenia, Negative Symptoms, Assessment
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with schizophrenia have negative symptoms and as such

(Kirkpatrick et al., 2011). However further study is required

assessment by the full CAINS is not always feasible and

to ascertain whether the item meaningfully differentiates

pragmatic (Park et al., 2012). With methods that can

between the two aforementioned populations (Kirkpatrick

quickly and efficiently screen patients that may require

et al., 2011).

further assessment being both practical and efficient. As
such Park and colleagues (2012) recently developed and
trialled at brief self-report version of the CAINS (CAINS-SR).
The results indicated that the experience subscale was
psychometrically sound whereas the expression subscale
exhibited poorer psychometric properties (Park et al.,
2012). Nonetheless the authors concluded that the
preliminary results indicated the potential of the CAINS-SR
with further work and validation (Park et al., 2012).
In addition to the development of the CAINS and the
CAINS-SR the original expert panel sought to develop a
concise measure of negative symptoms; specifically a
measure that would be appropriate for use in both
inpatient and outpatient clinical trials and sensitive to
change over time (Kirkpatrick et al., 2011). Thus the Brief
Negative Symptom Scale (BNSS) was developed
(Kirkpatrick et al., 2011; Strauss et al., 2012). Following
from the CAINS the BNSS also sought to measure the five
domains of negative symptoms, to employ a distinction
between anticipatory and consummatory experience of
pleasure as well as a differentiation between internal

Similar to the CAINS the BNSS was also found to have a two
factor structure in Kirkpatrick and colleague's (2011)
preliminary study. Recently Strauss and colleague's (2012)
conducted a study to further test the factor structure of the
BNSS. The results also indicated a two factor structure
similar to the CAINS with one factor reflecting amotivation
and pleasure and the other factor indicative of emotional
expression (Strauss et al., 2012).
In sum it is clearly apparent that recent efforts have seen
the development and as such advancement in the
assessment and measurement of negative symptoms.
However additional research is necessary to further test
and validate the psychometric properties of the newly
developed measures coupled with further delineation of
the boundaries of the negative symptom construct.
Moreover efforts need to be made to consolidate upon the
gains accomplished through the development of new
measures for the assessment of negative symptoms. Key
challenges in the area of the assessment of negative
symptoms are detailed in Table 3 below.

experiences and behaviour (Kirkpatrick et al., 2011).

The Treatment of Negative Symptoms

Further in addition to being concise; so the measure is

Currently there exists no agreed upon, empirically founded

feasible for use in large multi-centre clinical trials,

efficacious treatment for enduring (or primary) negative

Kirkpatrick and colleagues (2011) also aimed for the items

symptoms in schizophrenia (Kreyenbuhl et al., 2010). With

to be cross-culturally valid and the measure to be suitable

most antipsychotic trials generally focusing on positive

for use in other trials (such as epidemiological and

symptoms as the primary outcome measure (Tarrier &

psychological research).

Wykes, 2004), and few assessing the overall reduction in

The BNSS in addition to measuring the five domains of
negative symptoms specified by the original NIMH
consensus statement on negative symptoms (Kirkpatrick et
al., 2006) also incorporates a measure of distress
(Kirkpatrick et al., 2011; Strauss et al., 2012). The measure
of distress or lack of normal distress is included in an
attempt to differentiate between those that are suffering
from primary and secondary negative symptoms

Keywords : Schizophrenia, Negative Symptoms, Assessment
& Treatment - Shae-Leigh C Vella
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Challenge
Consistency in the assessment
of negative symptoms

Psychometric validation of the new
measures of negative symptoms

Differentiation of primary and
secondary negative symptoms

Research / Action Required
Adoption of the new measures
(CAINS, BNSS) to assess negative
symptoms both in research and
clinical practice.
Clarify and validate the psychometric
properties of the CAINS and BNSS.

Test the efficacy of distress in delineating
between primary and secondary
negative symptoms.
Theorise and test other modes for the
delineation between primary and
negative symptoms.

Implications
Facilitate the comparative evaluation of
different research studies and aid in the
translation of research into clinical practice.
Advancement of the field of negative
symptoms research through the provision
of psychometrically sound measures of
negative symptoms.
Delineation of the difference between
primary and secondary negative symptoms
will assist with the development of
treatments to target primary negative
symptoms.

Although both first and second generation antipsychotics

secondary negative symptoms and/or depressive

have generally been highly effective in the treatment of

symptoms (masked as negative symptoms) as oppose to

positive symptomology they are minimally effective in the

primary enduring negative symptoms. Further in addition

treatment of the negative domains of schizophrenia

to antipsychotic therapy several other pharmacological

(Tandon, Nasrallah & Keshavn, 2010). First generation anti-

strategies have been evaluated for the treatment of

psychotics or conventional neuroleptic treatments have

negative symptoms with some success thus far according

demonstrated negligible efficacy in the treatment of

to Tandon, Nasrallah and Keshavan (2010). Agents that

negative symptoms (Kelley, Haas, & van Kammen, 2008;

stimulate the NMDA glutamate receptor in combination

Tandon, Nasrallah & Keshavan, 2010). Some second

with antipsychotics have demonstrated some efficacy in

generation or atypical antipsychotics have demonstrated

the amelioration of negative symptoms (Tandon, Nasrallah

small effect sizes for the treatment of negative symptoms

& Keshavn, 2010). Further treatments that target the

in clinical trials (Buchanan et al., 2007; Kelley, Haas, & van

metabotropic glutamate receptors have also shown some

Kammen, 2008). However it remains unclear whether this

success (Tandon, Nasrallah & Keshavn, 2010).

reduction in negative symptoms is indicative of a reduction
of secondary negative symptoms through reducing
positive and depressive symptoms. Tandon, Nasrallah and
Keshavan (2010) argue that much of the effect of
antipsychotics upon negative symptoms is resultant from a
reduction of psychotic symptoms thus targeting secondary
negative symptoms not enduring primary negative
symptoms. Further they ascertain that antipsychotics have
no demonstrable efficacy against primary negative
symptoms or deficit syndrome (Kirkpatrick et al., 2006;
Tandon, Nasrallah & Keshavan, 2010).
Similarly a recent meta-analysis indicated that the
augmentation of antipsychotic therapy with an antidepressant was more effective than an antipsychotic alone
in the treatment of negative symptoms (Singh et al., 2010).
Thus the addition of the anti-depressant may be targeting
Keywords : Schizophrenia, Negative Symptoms, Assessment
& Treatment - Shae-Leigh C Vella

Recently Noroozian and colleagues (2013) tested the
efficacy of the augmentation of risperidone treatment with
tropisetron an anti-emetic drug for chemotherapy-induced
and postoperative emesis for the treatment of primary
negative symptoms. The results indicated that the
tropisetron addition to treatment improved the primary
negative symptoms of individuals with chronic stable
schizophrenia. Thus the preliminary results support the
efficacy of this addition to risperidone and further research
should be conducted to verify theses preliminary results.
Despite the lack of empirical data, clinical guidelines
indicate the most effective treatment for schizophrenia
generally is a continued care approach incorporating
antipsychotic medication and psychosocial intervention
such as cognitive behavioural therapy, social skills training,
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family interventions and supported employment (Lehman,

the need to be able to differentiate between primary and

Lieberman, Dixon, & et al., 2004; Mojtabai, Nicholson, &

secondary negative symptoms in order to advance

Carpenter, 1998). However, real world studies in hospital

treatment prospects. Recently Bell and colleagues' (2013)

and community settings demonstrate that this rarely

based upon the results of their empirical study

occurs (Drake, Bond, & Essock, 2009; Mojtabai et al., 2009).

recommended that separate treatments both

Furthermore even when combined pharmacological and

pharmacological and psychosocial, be developed for

psychological treatment is offered; participation of

negative symptoms and social cognition. Similarly Strauss

individuals with prominent negative symptoms may be

and colleagues' (2013) recently conducted a study

difficult to facilitate and less efficacious due to the inherent

assessing whether negative symptoms are multi or uni-

nature of negative symptoms (Whittington, Barnes &

factorial. The results of their study indicated two separate

Kendall, 2010).

domains and unique negative symptom profiles; in

A variety of psychosocial individual and family treatment
programs have been developed and trialled for their ability
to reduce symptoms (in conjunction with antipsychotic
treatment) and have demonstrated modest effects in
comparison to treatment as usual for negative symptoms
(Klingberg et al., 2011; Pfammater, Junghan, & Brenner,
2006; Thorup et al., 2005). Recently Staring, ter Huurne
and van der Gaag (2013) in a small pilot study found a

accordance with the domains measured by the BNSS and
CAINS. Therefore they recommended that future studies
aiming to develop pharmacological treatments for
negative symptoms should attempt to treat these domains
of negative symptomology separately. As without reducing
the heterogeneity of negative symptoms; attempts to
develop and treat negative symptoms will remain
challenged (Strauss et al., 2013).

cognitive behavioural therapy treatment aimed at

As reviewed above it is apparent that some novel

targeting negative symptoms to be modestly effective in

approaches such as agents that target the glutamate

reducing negative symptomology; therefore further

receptors and rTMS are demonstrating some success in the

research is needed.

However, the delivery of these

treatment of negative symptoms. As such further work is

services to community patients is hindered by financial,

needed to both advance these novel approaches as well as

workforce and regulatory constraints within mental health

clarify the negative symptoms they are targeting (primary

systems. In addition to pharmacological and psychological

or secondary) as well as the negative symptom domains

interventions for the treatment of negative symptoms

that they are effective in reducing. Thus due to the extent

repetitive transcranial magnetic stimulation (rTMS) has

of the dearth of knowledge in this area no specific

also been trialled and is demonstrating some promise for

recommendations can be made for future research. Rather

the reduction of negative symptoms (Dlabac-de Lange,

efforts need to be made generally to develop and test

Knegtering & Aleman, 2010; Tandon, Nasrallah &

treatments both pharmacological and psychological for the

Keshavan, 2010).

treatment of primary negative symptoms.

In sum it is apparent that largely negative symptoms

Conclusion :

remain untreatable; especially primary negative

Important progress in research and translational research

symptoms. As such concerted efforts need to be made to

in particular has influenced practice in the treatment of

develop both pharmacological and psychological

schizophrenia in general. However the issues outlined in

inventions that will reduce not only secondary negative

this paper above highlight the pressing need for research

symptoms but more importantly primary negative

within the area of negative symptoms. Not only should

symptoms; due to the high level of functional impairment

research focus on the uncertainties in the negative

that such symptomology imposes. Akin to this challenge is

symptom construct, the assessment of negative symptoms
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as well as their treatment but efforts should be made also

conducted through the collaborative involvement and

to minimise the gap between evidence based intervention

information sharing of scientists from various disciplines,

and health service delivery (Drake & Essock, 2009).

along with health professionals from the community as

Schizophrenia is a multifactorial and complex disorder, and
no discipline has the skills, capacity and resources to fully
address the challenges outlined above in order to improve
the understanding and treatment of primary negative
sy m p t o m o l o g y i n s c h i zo p h re n i a .

T h e re fo re

multidisciplinary collaborative research is necessary to
address the challenges evident pertaining to negative
symptoms. As the area requires research that can only be

well as mental health consumers. Although the process of
collaboration is not simple, with a number of significant
barriers that inhibits the collaborative process. Efforts need
to be made to overcome these barriers to address the
dearth of knowledge regarding the nature, assessment and
treatment of the negative symptoms in schizophrenia and
hence improve the quality of life of individuals with
schizophrenia who experience primary negative
symptoms.
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